4/A: BioXcel Therapeutics Executive Corrects Stock Unit Transaction in Amended SEC Filing
SEC Filing Amendment
Matthew T. Wiley, Chief Commercial Officer of BioXcel Therapeutics, files an amended SEC Form 4/A to correct a previous filing regarding the disposition of Restricted Stock Units (RSUs).
Summary
- Matthew T. Wiley, the Chief Commercial Officer of BioXcel Therapeutics, Inc. (BTAI), filed an amendment to a previous SEC Form 4 filing.
- The amendment, filed on September 17, 2024, corrects an error in the original filing from June 18, 2024, regarding the disposition of 750 Restricted Stock Units (RSUs).
- The original filing incorrectly indicated that these securities were acquired, while the amended filing clarifies that they were disposed of.
- The total number of derivative securities beneficially owned following the reported transaction remains unchanged from the original filing, with 8,250 RSUs held directly.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing correcting a previous error. While the error itself is slightly negative, the correction demonstrates transparency and compliance, resulting in a neutral to slightly positive sentiment.
Negatives
- The original SEC filing contained an error regarding the disposition of 750 Restricted Stock Units.
Industry Context
SEC filings are a routine part of corporate governance, and amendments are sometimes necessary to correct errors or provide additional information. This filing indicates a commitment to transparency and regulatory compliance by BioXcel Therapeutics.
Key Dates
| Date | Description |
|---|---|
| March 15, 2023 | Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter |
| June 15, 2024 | Date of earliest transaction. |
| June 18, 2024 | Date of original Form 4 filed with incorrect information. |
| September 17, 2024 | Date of amended Form 4/A filing to correct the error. |
Keywords
SEC Form 4/A, BioXcel Therapeutics, BTAI, Matthew T. Wiley, Restricted Stock Units, RSUs, Disposition, Amendment, Chief Commercial Officer, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.